Literature DB >> 30199097

Antigen-specific active immunotherapy for ovarian cancer.

Sterre T Paijens1, Ninke Leffers, Toos Daemen, Wijnand Helfrich, H Marike Boezen, Ben J Cohlen, Cornelis Jm Melief, Marco de Bruyn, Hans W Nijman.   

Abstract

BACKGROUND: This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9).Despite advances in chemotherapy, the prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce tumour antigen-specific anti-tumour immune responses as an alternative treatment for ovarian cancer.
OBJECTIVES: Primary objective• To assess the clinical efficacy of antigen-specific active immunotherapy for the treatment of ovarian cancer as evaluated by tumour response measured by Response Evaluation Criteria In Solid Tumors (RECIST) and/or cancer antigen (CA)-125 levels, response to post-immunotherapy treatment, and survival differences◦ In addition, we recorded the numbers of observed antigen-specific humoral and cellular responsesSecondary objective• To establish which combinations of immunotherapeutic strategies with tumour antigens provide the best immunological and clinical results SEARCH
METHODS: For the previous version of this review, we performed a systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL; 2009, Issue 3), in the Cochrane Library, the Cochrane Gynaecological Cancer Group Specialised Register, MEDLINE and Embase databases, and clinicaltrials.gov (1966 to July 2009). We also conducted handsearches of the proceedings of relevant annual meetings (1996 to July 2009).For the first update of this review, we extended the searches to October 2013, and for this update, we extended the searches to July 2017. SELECTION CRITERIA: We searched for randomised controlled trials (RCTs), as well as non-randomised studies (NRSs), that included participants with epithelial ovarian cancer, irrespective of disease stage, who were treated with antigen-specific active immunotherapy, irrespective of type of vaccine, antigen used, adjuvant used, route of vaccination, treatment schedule, and reported clinical or immunological outcomes. DATA COLLECTION AND ANALYSIS: Two reviews authors independently extracted the data. We evaluated the risk of bias for RCTs according to standard methodological procedures expected by Cochrane, and for NRSs by using a selection of quality domains deemed best applicable to the NRS. MAIN
RESULTS: We included 67 studies (representing 3632 women with epithelial ovarian cancer). The most striking observations of this review address the lack of uniformity in conduct and reporting of early-phase immunotherapy studies. Response definitions show substantial variation between trials, which makes comparison of trial results unreliable. Information on adverse events is frequently limited. Furthermore, reports of both RCTs and NRSs frequently lack the relevant information necessary for risk of bias assessment. Therefore, we cannot rule out serious biases in most of the included trials. However, selection, attrition, and selective reporting biases are likely to have affected the studies included in this review. GRADE ratings were high only for survival; for other primary outcomes, GRADE ratings were very low.The largest body of evidence is currently available for CA-125-targeted antibody therapy (17 studies, 2347 participants; very low-certainty evidence). Non-randomised studies of CA-125-targeted antibody therapy suggest improved survival among humoral and/or cellular responders, with only moderate adverse events. However, four large randomised placebo-controlled trials did not show any clinical benefit, despite induction of immune responses in approximately 60% of participants. Time to relapse with CA-125 monoclonal antibody versus placebo, respectively, ranged from 10.3 to 18.9 months versus 10.3 to 13 months (six RCTs, 1882 participants; high-certainty evidence). Only one RCT provided data on overall survival, reporting rates of 80% in both treatment and placebo groups (three RCTs, 1062 participants; high-certainty evidence). Other small studies targeting many different tumour antigens have presented promising immunological results. As these strategies have not yet been tested in RCTs, no reliable inferences about clinical efficacy can be made. Given the promising immunological results and the limited side effects and toxicity reported, exploration of clinical efficacy in large well-designed RCTs may be worthwhile. AUTHORS'
CONCLUSIONS: We conclude that despite promising immunological responses, no clinically effective antigen-specific active immunotherapy is yet available for ovarian cancer. Results should be interpreted cautiously, as review authors found a significant dearth of relevant information for assessment of risk of bias in both RCTs and NRSs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30199097      PMCID: PMC6513204          DOI: 10.1002/14651858.CD007287.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  130 in total

1.  A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Authors:  Mahsa Mohebtash; Kwong-Yok Tsang; Ravi A Madan; Ngar-Yee Huen; Diane J Poole; Caroline Jochems; Jacquin Jones; Theresa Ferrara; Christopher R Heery; Philip M Arlen; Seth M Steinberg; Mary Pazdur; Myrna Rauckhorst; Elizabeth C Jones; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

2.  Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.

Authors:  G D MacLean; M B Bowen-Yacyshyn; J Samuel; A Meikle; G Stuart; J Nation; S Poppema; M Jerry; R Koganty; T Wong
Journal:  J Immunother (1991)       Date:  1992-05

3.  Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Authors:  Junko Matsuzaki; Takemasa Tsuji; Immanuel Luescher; Lloyd J Old; Protul Shrikant; Sacha Gnjatic; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2013-12-17       Impact factor: 11.151

4.  Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells.

Authors:  Samuel D Bernal; Enrique T Ona; Aileen Riego-Javier; Romulo DE Villa; Gloria R Cristal-Luna; Josephine B Laguatan; Eunice R Batac; Oscar Q Canlas
Journal:  Oncol Lett       Date:  2011-09-20       Impact factor: 2.967

5.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Authors:  K L Knutson; K Schiffman; M L Disis
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

6.  Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.

Authors:  Jonathan Oh; Minal Barve; Carolyn M Matthews; E Colin Koon; Thomas P Heffernan; Bruce Fine; Elizabeth Grosen; Melanie K Bergman; Evelyn L Fleming; Leslie R DeMars; Loyd West; Daniel L Spitz; Howard Goodman; Kenneth C Hancock; Gladice Wallraven; Padmasini Kumar; Ernest Bognar; Luisa Manning; Beena O Pappen; Ned Adams; Neil Senzer; John Nemunaitis
Journal:  Gynecol Oncol       Date:  2016-09-24       Impact factor: 5.482

7.  Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.

Authors:  Scott J Antonia; Noweeda Mirza; Ingo Fricke; Alberto Chiappori; Patricia Thompson; Nicholas Williams; Gerold Bepler; George Simon; William Janssen; Ji-Hyun Lee; Kerstin Menander; Sunil Chada; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

8.  Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Authors:  Dan Laheru; Eric Lutz; James Burke; Barbara Biedrzycki; Sara Solt; Beth Onners; Irena Tartakovsky; John Nemunaitis; Dung Le; Elizabeth Sugar; Kristen Hege; Elizabeth Jaffee
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

9.  CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.

Authors:  M B Yacyshyn; S Poppema; A Berg; G D MacLean; M A Reddish; A Meikle; B M Longenecker
Journal:  Int J Cancer       Date:  1995-05-16       Impact factor: 7.396

10.  First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

Authors:  Neil L Berinstein; Mohan Karkada; Michael A Morse; John J Nemunaitis; Gurkamal Chatta; Howard Kaufman; Kunle Odunsi; Rita Nigam; Leeladhar Sammatur; Lisa D MacDonald; Genevieve M Weir; Marianne M Stanford; Marc Mansour
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531

View more
  5 in total

Review 1.  Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.

Authors:  Sarah Nersesian; Haley Glazebrook; Jay Toulany; Stephanie R Grantham; Jeanette E Boudreau
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

2.  Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.

Authors:  Dmitriy Zamarin; Sven Walderich; Aliya Holland; Qin Zhou; Alexia E Iasonos; Jean M Torrisi; Taha Merghoub; Lewis F Chesebrough; Autumn S Mcdonnell; Jacqueline M Gallagher; Yanyun Li; Travis J Hollmann; Rachel N Grisham; Courtney L Erskine; Mathew S Block; Keith L Knutson; Roisin E O'Cearbhaill; Carol Aghajanian; Jason A Konner
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 3.  Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.

Authors:  Seiji Mabuchi; Tomoyuki Sasano; Naoko Komura
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

4.  Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer.

Authors:  Christine De Bruyn; Jolien Ceusters; Chiara Landolfo; Thaïs Baert; Gitte Thirion; Sandra Claes; Ann Vankerckhoven; Roxanne Wouters; Dominique Schols; Dirk Timmerman; Ignace Vergote; An Coosemans
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

5.  Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment.

Authors:  Er Yue; Guangchao Yang; Yuanfei Yao; Guangyu Wang; Atish Mohanty; Fang Fan; Ling Zhao; Yanqiao Zhang; Tamara Mirzapoiazova; Tonya C Walser; Lorna Rodriguez-Rodriguez; Yuman Fong; Ravi Salgia; Edward Wenge Wang
Journal:  Cancers (Basel)       Date:  2021-08-24       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.